What is Rutherford 6 (chronic limb-threatening ischemia classification)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Rutherford 6: Major Tissue Loss in Chronic Limb-Threatening Ischemia

Rutherford 6 represents the most severe category of chronic limb-threatening ischemia (CLTI), characterized by major tissue loss including extensive ulceration or gangrene, and carries the highest risk of limb amputation and death. 1

Classification Definition

Rutherford 6 is defined by the presence of major tissue loss in the setting of peripheral artery disease (PAD), distinguishing it from Rutherford 5 which involves only minor tissue loss. 1

  • This classification corresponds to Fontaine Stage IV (ulceration or gangrene) 1
  • Rutherford 6 represents the threshold beyond which limb salvage becomes significantly more challenging 1
  • Symptoms must be present for greater than 2 weeks to distinguish from acute limb ischemia 1

Clinical Presentation

Patients with Rutherford 6 present with extensive nonhealing wounds, ulceration, or gangrene affecting major portions of the foot or leg, often accompanied by severe ischemic rest pain. 1

  • Rest pain is typically located in the foot or toes and worsens when lying down 1
  • Pain can be profound and seriously disrupts sleep 1
  • The tissue loss is more extensive than the minor tissue loss seen in Rutherford 5 1
  • Wounds may involve multiple locations including heel, forefoot, toes, or calf/ankle 2

Prognostic Implications

Rutherford 6 classification independently predicts significantly worse outcomes compared to less severe categories, with substantially higher rates of amputation and mortality. 2

  • Rutherford 6 is an independent predictor of reduced primary patency (HR 4.7,95% CI 1.5-14.8) 2
  • It independently predicts reduced assisted patency (HR 5.39,95% CI 1.74-16.73) 2
  • Rutherford 6 is independently associated with reduced limb salvage (HR 35.1,95% CI 5.4-231.2) and amputation-free survival (HR 3.61,95% CI 1.4-9.18) 2
  • Historical 1-year mortality rates range from 25-35% and 1-year amputation rates up to 30% in CLTI patients 1

Management Approach

Urgent referral to a vascular specialist and multidisciplinary team is mandatory for Rutherford 6 patients, as early recognition and intervention significantly improve limb salvage rates. 1

  • Infra-popliteal revascularization is indicated for limb salvage in CLTI 1
  • Revascularization is associated with significantly better outcomes: limb amputation rates of 40.6% with revascularization versus 46.5% without (P < 0.001) 3
  • Bypass using great saphenous vein is the preferred revascularization method for infra-popliteal arteries (Class I, Level A recommendation) 1
  • Angiography including foot runoff should be considered prior to revascularization in below-the-knee lesions 1

Critical Pitfalls

The most common pitfall is delayed referral to vascular specialists, as Rutherford 6 patients require urgent evaluation within days, not weeks, to maximize limb salvage potential. 1

  • Patients with extensive necrosis, infectious gangrene, or severe comorbidities may require primary major amputation rather than revascularization attempts 1
  • Multidisciplinary care improves amputation-free survival by greater than twofold compared to standard wound care (HR 2.664,95% CI 1.23-5.77) 4
  • Optimal glycemic control is essential in diabetic patients with CLTI 1
  • Wound healing remains prolonged (444.5 ± 33.2 days in multidisciplinary care) even with successful revascularization 4

Related Questions

What is the diagnosis for a 55-year-old male active smoker (tobacco user) with 80 pack-years of smoking history, presenting with a non-healing wound on the toes, rest pain, 3-4/5 muscle weakness in the left leg, and atrial fibrillation (irregular heart rhythm) on electrocardiogram (ECG), but no evidence of active ischemic heart disease (negative troponin I, no hypokinesia on echocardiogram)?
What is the management approach for Chronic Limb-Threatening Ischemia (CLTI)?
What are the management strategies for Chronic Limb-Threatening Ischemia (CLTI) and its clinical symptoms?
What is Chronic Limb-Threatening Ischemia (CLTI)?
Is the requested inpatient stay and deep venous arterialization (DVA) medically necessary for a patient with critical limb-threatening ischemia (CLTI) and a history of hypertension (HTN), hyperlipidemia (HLD), heart failure with reduced ejection fraction (HFrEF), diabetes mellitus (DM), end-stage renal disease (ESRD), and peripheral artery disease (PAD)?
What is the definition of heart failure and when should it be coded in patients, particularly those with a history of hypertension, diabetes, or coronary artery disease (CAD)?
What is the best course of action for a male patient with diabetes mellitus type II, hypertension, and hyperlipidemia, who has shown an increase in Hemoglobin A1c (HbA1c) from 9.6% to 10.2% despite reported compliance with his current medication regimen of Farxiga (dapagliflozin) 10 mg once a day, metformin 1000 mg twice a day, and Basaglar (insulin glargine) 68 units subcutaneously (SQ) once a day?
What is the best treatment approach for an osteoporotic patient with a non-union metatarsal fracture, not currently taking bisphosphonates (bone density conservation medications)?
What medications should be suspended or modified before surgery in patients with a history of bleeding disorders or those taking anticoagulant medications, non-steroidal anti-inflammatory drugs (NSAIDs), or oral hypoglycemic medications?
What are the next steps for a 30-year-old female patient with suspected Deep Infiltrating Endometriosis (DIE), Ehlers-Danlos Syndrome (EDS), and a history of bowel adhesions, who is scheduled for a pelvic Magnetic Resonance Imaging (MRI) and endometriosis excision surgery?
What is the mechanism of action of stimulant medications, such as methylphenidate (Ritalin) and amphetamines, in treating Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.